ALT5 Sigma (NASDAQ:AIFC) Releases Earnings Results

ALT5 Sigma (NASDAQ:AIFC) announced its earnings results on Monday. The company reported $0.42 earnings per share (EPS) for the quarter, Zacks reports. ALT5 Sigma had a negative return on equity of 68.25% and a negative net margin of 2,483.94%.

ALT5 Sigma Stock Performance

ALT5 Sigma stock opened at $0.47 on Wednesday. The stock’s fifty day moving average price is $0.53 and its two-hundred day moving average price is $0.95. ALT5 Sigma has a one year low of $0.36 and a one year high of $8.74. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.82 and a current ratio of 0.82.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Balyasny Asset Management L.P. bought a new stake in ALT5 Sigma during the fourth quarter worth $26,000. Victory Capital Management Inc. acquired a new position in ALT5 Sigma during the third quarter worth about $33,000. Captrust Financial Advisors raised its stake in ALT5 Sigma by 116.3% during the fourth quarter. Captrust Financial Advisors now owns 37,300 shares of the company’s stock worth $41,000 after acquiring an additional 20,054 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in shares of ALT5 Sigma in the third quarter worth about $45,000. Finally, Arkadios Wealth Advisors lifted its holdings in shares of ALT5 Sigma by 80.1% in the fourth quarter. Arkadios Wealth Advisors now owns 41,620 shares of the company’s stock worth $46,000 after acquiring an additional 18,510 shares during the last quarter. 6.27% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of ALT5 Sigma in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.

About ALT5 Sigma

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.